Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Practice Point
Nature Reviews Neurology 1, 20–21 (1 November 2005) | doi:10.1038/ncpneuro0039
Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment?
Abstract
Thal LJ et al. (2005) A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30: 1204–1215 Synopsis Background Clinical studies have failed to show convincing effects of nonsteroidal anti-inflammatory drugs (NSAIDs)—including the selective cyclo-oxygenase 2 (COX2) inhibitor rofecoxib—on the progression of Alzheimer's disease (AD).
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
